This week we dive deep into an article in JAMA IM on falsified data in meta-analyses. We also discuss the recent JAMA viewpoint "Reducing the Expert Halo Effect on Pharmacy and Therapeutics Committees" with its author, Dr. Stephanie Halvorson of OHSU.

In this bonus episode, we bring back Dr. Tom Beer of OHSU from episode 1.33 to discuss how to manage your personal finances. The interview is aimed at young physicians, but there is something for all audiences as we cover a broad range of topics: paying off loans, optimizing retirement savings, buying a home, and investing.

This week's episode begins with praise for the recent article by Booth CM, Karim S, and Mackillop WJ on real-world data published in Nature Reviews Clinical Oncology. Next, we tackle the resignation of Scott Gottlieb as FDA commissioner and how we can measure the success of the FDA. Finally, we have an interview with Dr. Deborah Cohen of OHSU on effective communication between the clinician and the patient and how we can use data from the Electronic Health Record to make meaningful improvements in care.

This BONUS episode is the recording of a lecture given as part of the medical school class Appraising Medical Literature, taught at OHSU. This clip from the class critiques the recent JAMA Pediatrics paper "Association Between Screen Time and Children’s Performance on a Developmental Screening Test".

In this episode we discuss the controversy over the recent article in NEJM, "Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors", with Dr. Tom Deloughery of OHSU. We end with an interview with Dr. John McConnell, also of OHSU, on health economics and Medicaid.

In the first half of this episode, Dr. Sven Olson of OHSU joins us to help critique the recent NEJM paper, "Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura". In the second half, we interview Dr. Inmaculada Hernández of the University of Pittsburgh on her work on the economic principles behind runaway drug prices.

We feature two interviews this week: the first is a hallway conversation with [soon-to-be] Dr. Antonious Hazim of OHSU on the Declaration of Geneva and the second is a discussion with [soon-to-be] Dr. Joshua Niforatos on his recent paper in The American Journal of Emergency Medicine, titled "Financial relationships with industry among guideline authors for the management of acute ischemic stroke".

This episode features an interview with hematologist Dr. Thomas Deloughery of OHSU. We cover a broad range of topics including 23andMe, wilderness medicine, academia, and Twitter. We'll be back next week with our regular introductory monologue!

In this episode we interview Dr. Alex Denes of OHSU on his decades-long career in medicine: what practices have changed and what have stayed the same. No monologue this week - we'll be back next week with more insights!

In this episode we tackle Eli Lilly's drug Lartruvo (olaratumab) and the under-powered phase II trial that led to its FDA accelerated approval; a viewpoint in JAMA on new directions for cancer trials; and gene expression profiling for carcinoma of unknown primary. We end with an interview with Dr. Miriam Knoll of Hackensack Meridian Health on employment after residency or fellowship, residency training, and the medical specialty pipeline.

This week we dive into the recent paper by Drs. Cole and Dusetzina titled "Generic Price Competition For Specialty Drugs: Too Little, Too Late?". We also have an interview with Dr. Martin Schreiber of OHSU on his experiences as a trauma surgeon, both stateside and on the battlefield.

In this episode, we discuss two recent papers published in the Journal of Clinical Oncology: ECOG-ACRIN 2511 and the update adding overall-survival and crossover results to KEYNOTE-024. We end with an interview with Dr. Joseph Shatzel of OHSU on mentorship.

In this episode we discuss guarantee-time bias in the context of the recent JAMA Oncology paper titled "Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer". We also have an interview with Dr. Tom Beer, the Deputy Director of the OHSU Knight Cancer Institute, on clinical trials, leadership, philanthropy, and future directions in cancer research.

Episode 1.32 ran a little long, so this is episode 1.32.1 - we broke out the interview with Dr. Brian Kavanagh, the Chairman of Radiation Oncology at the University of Colorado, to make the interview more accessible.

This week we discuss various academic indices including the h-index and the new Altmetric score, and we go over the recent NY Times article on conflict of interest. We end with an interview with Dr. Brian Kavanagh, the Chairman of Radiation Oncology at the University of Colorado.

We begin this episode with a discussion of Dr. Mukherjee's ongoing study combining a ketogenic diet with PI3 kinase inhibition. We continue with a take on a recent reanalysis of COMET-1 and COMET-2, two failed randomized controlled trials of cabozantinib versus prednisone or mitoxantrone-prednisone in metastatic castration-resistant prostate cancer. We end with an interview on instabilities in the health insurance marketplace with Dr. Jane Zhu of OHSU, an expert in the Affordable Care Act.

We begin this episode with a critique of the recent paper in the BMJ, "Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial" and we end it with an interview with Dr. Andre Mansoor, discussing his new book: "Frameworks for Internal Medicine."

Parachutes: https://www.bmj.com/content/363/bmj.k5094

In this episode we critique two recent FDA drug approvals (venetoclax in combination with azacitidine or decitabine or low-dose cytarabine; glasdegib in combination with low-dose cytarabine -- both for acute myeloid leukemia)and we interview Dr. Chadi Nabhan, the Chief Medical Officer of Cardinal Health, on career transitions. The interview was taped on location at the 2018 annual conference of the American Society of Hematology in San Diego.

Having just returned from the 2018 American Society of Hematology (ASH) Annual Meeting, we begin this episode by discussing the abstract of a study that stretches its conclusions. We dedicate most of the episode to an interview with Dr. Sima Desai, the program director for OHSU's Internal Medicine Residency Program. She gives some great insight on the program's inner workings.

In this episode we discuss: Dr. Gilbert Welch's Wikipedia page and how we should keep his decades of work in perspective, a Twitter conversation between experts on differing interpretations of results from next-generation sequencing, the new paper in JAMA titled "Assessment of Pregabalin Postapproval Trials and the Suggestion of Efficacy for New Indications", and finally, along with Dr. Sam Edwards of OHSU, we criticize the recent perspective piece in NEJM titled "Beyond Evidence-Based Medicine".